Literature DB >> 12610164

Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation.

Peter R Meyer1, Johan Lennerstrand, Suzanne E Matsuura, Brendan A Larder, Walter A Scott.   

Abstract

Finger insertion mutations of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) (T69S mutations followed by various dipeptide insertions) have a multinucleoside resistance phenotype that can be explained by decreased sensitivity to deoxynucleoside triphosphate (dNTP) inhibition of the nucleotide-dependent unblocking activity of RT. We show that RTs with SG or AG (but not SS) insertions have three- to fourfold-increased unblocking activity and that all three finger insertion mutations have threefold-decreased sensitivity to dNTP inhibition. The additional presence of M41L and T215Y mutations increased unblocking activity for all three insertions, greatly reduced the sensitivity to dNTP inhibition, and resulted in defects in in vitro DNA chain elongation. The DNA chain elongation defects were partially repaired by additional mutations at positions 210, 211, and 214. These results suggest that structural communication between the regions of RT defined by these mutations plays a role in the multinucleoside resistance phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610164      PMCID: PMC149510          DOI: 10.1128/jvi.77.6.3871-3877.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.

Authors:  J Lennerstrand; D K Stammers; B A Larder
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors.

Authors:  B Masquelier; E Race; C Tamalet; D Descamps; J Izopet; C Buffet-Janvresse; A Ruffault; A S Mohammed; J Cottalorda; A Schmuck; V Calvez; E Dam; H Fleury; F Brun-Vézinet
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase.

Authors:  C Isel; C Ehresmann; P Walter; B Ehresmann; R Marquet
Journal:  J Biol Chem       Date:  2001-10-19       Impact factor: 5.157

4.  Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.

Authors:  J Lennerstrand; K Hertogs; D K Stammers; B A Larder
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Prevalence and genetic heterogeneity of the reverse transcriptase T69S-S-X insertion in pretreated HIV-infected patients.

Authors:  C Briones; A Mas; M Pérez-Olmeda; C Altisent; E Domingo; V Soriano
Journal:  Intervirology       Date:  2001       Impact factor: 1.763

6.  Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.

Authors:  P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.

Authors:  K Van Vaerenbergh; K Van Laethem; J Albert; C A Boucher; B Clotet; M Floridia; J Gerstoft; B Hejdeman; C Nielsen; C Pannecouque; L Perrin; M F Pirillo; L Ruiz; J C Schmit; F Schneider; A Schoolmeester; R Schuurman; H J Stellbrink; L Stuyver; J Van Lunzen; B Van Remoortel; E Van Wijngaerden; S Vella; M Witvrouw; S Yerly; E De Clercq; J Destmyer; A M Vandamme
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

8.  Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.

Authors:  V V Lukashov; R Huismans; M F Jebbink; S A Danner; R J de Boer; J Goudsmit
Journal:  AIDS Res Hum Retroviruses       Date:  2001-06-10       Impact factor: 2.205

9.  Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Peter R Meyer; Suzanne E Matsuura; Adviye A Tolun; Ingrid Pfeifer; Antero G So; John W Mellors; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

10.  Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance.

Authors:  A Mas; M Parera; C Briones; V Soriano; M A Martínez; E Domingo; L Menéndez-Arias
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

View more
  24 in total

1.  Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants.

Authors:  Peter R Meyer; Anthony J Smith; Suzanne E Matsuura; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 2.  Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Authors:  Mark A Winters; Thomas C Merigan
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.

Authors:  Johan Lennerstrand; Chung K Chu; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

4.  Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

Authors:  Francine Bouchonnet; Elisabeth Dam; Fabrizio Mammano; Vaea de Soultrait; Gaëlle Henneré; Henri Benech; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.

Authors:  Maryam Ehteshami; Monique Nijhuis; Jean A Bernatchez; Christopher J Ablenas; Suzanne McCormick; Dorien de Jong; Dirk Jochmans; Matthias Götte
Journal:  J Biol Chem       Date:  2013-04-18       Impact factor: 5.157

6.  4'-C-methyl-2'-deoxyadenosine and 4'-C-ethyl-2'-deoxyadenosine inhibit HIV-1 replication.

Authors:  B Christie Vu; Paul L Boyer; Maqbool A Siddiqui; Victor E Marquez; Stephen H Hughes
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

7.  Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.

Authors:  Paul L Boyer; Tomozumi Imamichi; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

9.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

10.  Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance.

Authors:  Kalyan Das; Rajiv P Bandwar; Kirsten L White; Joy Y Feng; Stefan G Sarafianos; Steven Tuske; Xiongying Tu; Arthur D Clark; Paul L Boyer; Xiaorong Hou; Barbara L Gaffney; Roger A Jones; Michael D Miller; Stephen H Hughes; Eddy Arnold
Journal:  J Biol Chem       Date:  2009-10-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.